Lansen Pharmaceutical : POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 13 JULY 2016

Microsoft Word - Lansen - poll results annoucement (resolutions passed)

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

LANSEN PHARMACEUTICAL HOLDINGS LIMITED 朗生醫藥控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 503) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 13 JULY 2016

The Board is pleased to announce that all the resolutions as set out in the Notice were duly passed at the EGM held on 13 July 2016.

Reference is made to the circular (the "Circular") and the notice of extraordinary general meeting ("Notice") of Lansen Pharmaceutical Holdings Limited (the "Company") dated 28 June 2016. Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Circular.

The board of directors (the "Board") of the Company is pleased to announce that at the extraordinary general meeting of the Company held on 13 July 2016 (the ''EGM''), the proposed resolutions (1) and (2) set out in the Notice were duly passed by the Independent Shareholders by way of poll.

As at the date of the EGM, the total issued share capital of the Company was 415,000,000 Shares. CIH and its associates were required to abstain and had abstained from voting on the proposed resolutions (1) and (2) as set out in the Notice. Therefore, the number of Shares entitling the Independent Shareholders to attend and vote for or against the proposed resolutions (1) and (2) at the EGM was 205,180,000 Shares (representing approximately 49% of the entire issued share capital of the Company).

The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)
		For	Against
1.	To authorize the directors of the Company to	48,471,100	6,000
	complete the Second Tranche Subscription in	(99.99%)	(0.01%)
	accordance with the terms of the subscription
	agreement dated 24 March 2016 at any time
	within six months from the date this resolution is
	passed (capitalised terms used herein shall have
	the same meanings as defined in the Notice).
2.	To approve the cross guarantee agreement dated	46,179,100	2,298,000
	24 June 2016 entered into between Jilin Haizi	(95.26%)	(4.74%)
	Biotechnology Limited, Ningbo Liwah
	Pharmaceutical Company Limited and Lansen
	Pharmaceutical Holdings Limited (a wholly
	owned subsidiary of the Company), the
	proposed caps as described in the circular of the
	Company to the Shareholders dated 28 June
	2016 and the transaction thereunder.

As more than 50% of the votes were cast in favour of resolutions (1) and (2) above, resolutions (1) and (2) were duly passed as ordinary resolutions.

Save as disclosed above, there were no Shares: (i) entitling its Shareholder to attend and abstain from voting in favour as set out in Rule 13.40 of the Listing Rules; (ii) whose Shareholder is required under the Listing Rules to abstain from voting; and (iii) whose Shareholder has stated its intention in the Circular to vote against or abstain from voting on the resolutions at the EGM.

The Company's Branch Share Registrar in Hong Kong, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM.

By order of the Board

Lansen Pharmaceutical Holdings Limited Stephen Burnau Hunt

Chairman

Hong Kong, 13 July 2016

As at the date of this announcement, the executive Directors are Mr. Liu Bang Min and Mr. Hou Song; the non- executive Directors are Mr. Stephen Burnau Hunt, Mr. Lee Jin Yi, Mr. Tang Jun and Ms. Liu Xuezi; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Tang Chiu Ping, Raymond and Mr. Fritz Heinrich Horlacher.